01/26/23 9:42 PMNasdaq : BIOA, B European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease: BioArcticBioArctic AB's partner Eisai announced today that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of Early Alzheimer's disease with confirmed amyloid pathology, for review following a standard timeline.RHEA-AIvery positive
01/25/23 3:32 AMNasdaq : BIOA, B conferencesearningsInvitation to presentation of BioArctic's fourth quarter report for October - December 2022 on October 20 at 9.30 a.m. CETBioArctic AB will publish the company's fourth quarter report for October- December 2022 on Friday, February 3, 2022, at 08:00 a.m. CET.. In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference on February 3, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on...RHEA-AIneutral
01/15/23 9:56 PMNasdaq : BIOA, B BioArctic's partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer's disease in JapanBioArctic AB's partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD dementia with confirmed presence of amyloid pathology in the brain to the...RHEA-AIneutral
